This Article Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Reprints and Permissions Copyright Information Books from ASM Press MicrobeWorld Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Chimata, M Articles by Kakuta, S Search for Related Content PubMed PubMed Citation Articles by Chimata, M Articles by Kakuta, S

 Previous Article  |  Next Article 

Antimicrob Agents Chemother. 1993 February; 37(2): 229-233

Pharmacokinetics of meropenem in patients with various degrees of renal function, including patients with end-stage renal disease.

First Department of Medicine, Teikyo University School of Medicine, Tokyo, Japan.

ABSTRACT

The pharmacokinetics of meropenem were studied after intravenous infusion in 13 patients grouped according to the impairment of their renal function. Creatinine clearance (CLCR) was greater than 50, 50 to 30, and less than 30 ml/min in groups I, II, and III, respectively. Two other groups, groups IV and V, each comprising four patients with end-stage renal disease (CLCR, < 5 ml/min), were also studied, the former on days off of hemodialysis and the latter on days of hemodialysis. The elimination half-lives of meropenem were 1.54 +/- 0.70 h in group I patients, 3.36 +/- 1.02 h in group II patients, and 5.00 +/- 1.05 h in group III patients. Cumulative urinary excretion accounted for 48.5% of the dose in group I patients and decreased progressively with a decline in renal function. Hemodialysis shortened the elimination half-life of meropenem from 7.0 h to 2.9 h. H-4295, the main metabolite of meropenem, had a peak level in plasma of 0.5 to 1.0 h in patients with renal failure. The level of H-4295 decreased with hemodialysis. The dosing interval of meropenem should be prolonged in a regular proportion to the decline in CLCR (12 h in group II patients and 24 h in group III patients). In patients receiving hemodialysis, dosing after each hemodialysis session is recommended.

This article has been cited by other articles:

• Mallalieu, N. L., Lennon, S., Liu, M., Kirkpatrick, C., Robson, R., Luedin, E., Davies, B. E. (2008). Effect of Impaired Renal Function on the Pharmacokinetics of Tomopenem (RO4908463/CS-023), a Novel Carbapenem. Antimicrob. Agents Chemother. 52: 2360-2366 [Abstract] [Full Text]  
• Li, C., Kuti, J. L., Nightingale, C. H., Nicolau, D. P. (2006). Population pharmacokinetic analysis and dosing regimen optimization of meropenem in adult patients.. J Clin Pharmacol 46: 1171-1178 [Abstract] [Full Text]  
• Robatel, C., Decosterd, L. A., Biollaz, J., Eckert, P., Schaller, M. D., Buclin, T. (2003). Pharmacokinetics and Dosage Adaptation of Meropenem during Continuous Venovenous Hemodiafiltration in Critically Ill Patients. J Clin Pharmacol 43: 1329-1340 [Abstract] [Full Text]  
• Thalhammer, F., Schenk, P., Burgmann, H., El Menyawi, I., Hollenstein, U. M., Rosenkranz, A. R., Sunder-Plassmann, G., Breyer, S., Ratheiser, K. (1998). Single-Dose Pharmacokinetics of Meropenem during Continuous Venovenous Hemofiltration. Antimicrob. Agents Chemother. 42: 2417-2420 [Abstract] [Full Text]  
• Krueger, W. A., Schroeder, T. H., Hutchison, M., Hoffmann, E., Dieterich, H.-J., Heininger, A., Erley, C., Wehrle, A., Unertl, K. (1998). Pharmacokinetics of Meropenem in Critically Ill Patients with Acute Renal Failure Treated by Continuous Hemodiafiltration. Antimicrob. Agents Chemother. 42: 2421-2424 [Abstract] [Full Text]